Clinical trial backs VirtualPhenotype test:
This article was originally published in Clinica
Executive Summary
Virco says it now has the first evidence from a clinical trial to show that its VirtualPhenotype HIV drug resistance test is better than conventional genotyping tests at predicting the way HIV patients respond to therapy. The trial showed that the VirtualPhenotype test was a reliable and independent predictor of clinical outcome compared with a genotyping assay, which failed to predict outcome, reports the Cambridge, UK-based company. Virco's test involves combining the genetic information from a patient's virus with a large database of resistance information from previous virus samples to produce a resistance score for each drug.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.